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Objectives: Next Generation Sequencing (NGS) offers a potentially powerful plat-
form for extremely sensitive, high-throughput, multiplex, quantitative detection of 
nucleic acid biomarkers. While NGS currently represents a small portion of global 
clinical molecular diagnostic testing, new funding and reimbursement initiatives 
promise to accelerate its clinical utilization. Given increasing numbers of predic-
tive/ prognostic biomarkers but limited tissue and need for less invasive sample 
acuisition, NGS has the potential to transform personalized medicine (PM) and 
companion diagnostics. The current study characterized global NGS availability and 
reimbursement trends. Health technology assessments (HTAs) for NGS and other 
relevant multiplex/ gene panel tests were also studied for evolving evidence require-
ments. MethOds: Key health care provision, HTA agency, and payer websites in the 
EU, US, Australia and Canada were reviewed to identify NGS funding and reimburse-
ment initiatives, and relevant HTAs. In addition, a limited number of stakeholder 
interviews were conducted to help further characterize the evolving global NGS 
landscape. Results: A number of NGS funding and reimbursement initiatives 
were identified, especially France, Germany, UK, US and Australia. Initiatives have 
been mainly centered on funding of pilot clinical utility demonstrations through 
research and clinical use. In Germany and US, specific initiatives are underway to 
develop specific NGS reimbursement codes and payment rates. A number of HTAs 
for NGS and other multiplex/ gene panel test platforms were identified, primarily for 
oncology, cardiovascular, infectious disease, inherited disease, and neuropsychiatry 
applications. Key HTA concerns include test clinical utility, cost-effectiveness, real-
world reproducibility and equity of access given potential cost. cOnclusiOns: 
Payers and providers increasingly recognize NGS as enabling expanded adoption 
of PM approaches. As PM expands with increasing numbers of clinically actionable 
biomarkers, ensuring that test evidence development is aligned with expectations, 
and expectations with reality are key steps. Further, developing reimbursement/ 
funding mechanisms to support testing uptake will be critical in all markets.
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how iS reSearCh aNd develoPmeNt iNNovatioN evolviNG? FoCuS oN 
oNColoGy aNd CardiovaSCular diSeaSe
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By 2030, 50% of all deaths are expected to be caused by oncology, or cardiovascular 
diseases. Research and development therefore continues to evolve in these areas to 
provide a better answer to complex medical needs. As a consequence, the definition 
of innovation is evolving, going from therapeutic drugs with a new mode of action 
to novel biotechnologies, biological therapeutics, and vaccination. Objectives: 
We aim to investigate how therapies for oncology and cardiovascular diseases are 
expected to evolve in future into technologies that transform the concept of innova-
tion. MethOds: Data were extracted from Citeline to assess the scale of therapies 
in development including: vaccines, stem cells, antibodies, reformulation of combi-
nation therapy, gene therapy and RNAi. Results: In oncology, across the selected 
novel therapies, there are over 670 trials in preclinical to phase 3 of development. 
Vaccines have a higher rate of development with over 200 products in preclinical 
development to phase 3. Other areas of development include antibodies, and gene 
therapy, with over 30 therapies in phase 2 trials alone. Meanwhile, cardiovascular 
disease has fewer ongoing ‘novel therapy’ trials compared to oncology (around 75% 
fewer trials). The main areas of development include reformulation of fixed dose 
combinations, and stem cell research (a total of 60 trials, and 53 trials in preclinical 
to phase 3 respectively). The trend in innovation for cardiovascular disease instead 
tends to be focussed on integrated technology and medical devices. cOnclusiOns: 
While we are fairly acquainted with the current evaluation methods and relevance 
of clinical and economic evidence of traditional therapies, the emergence of new 
technologies creates uncertainties around how they will be assessed by payers. For 
example, demonstrating the value of vaccines (which avoid illness) is difficult to 
express. Industry must now consider factors outside of the current remit to prepare 
for successful market access.
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Objectives: It is controversial to use 5-year survival estimates to assess the pro-
gress in cancer prevention and control. The study aimed to analyze associations 
between 5-year survival, and two standard measures of cancer burden, incidence 
and mortality, based on publicly available population cancer statistics in England 
and Wales. MethOds: Sex-specific mortality and incidence of 14 types of com-
mon cancer between 1976 to 1995 were obtained from a national database on 
the UK Office for National Statistics website. Sex-specific 5-year survival data 
retrieved from the Cancer Research UK website databases. The relationships 
between 5-year survival, and incidence and mortality were estimated based on 
both Pearson and Spearman correlation coefficients. Results: From 1976 to 1995, 
all male and female cancer types showed increased 5-year survival, ranged from 
0.2% (pancreas and lung cancers) to 16.6% (prostate cancer) for males, and from 
Objectives: Colorectal cancer (CRR) is an important public health problem. The 
human and financial costs of this disease have prompted considerable research 
efforts to evaluate the ability of screening tests to detect the colorectal cancer at 
an early curable stage. It is now established that screening by faecal occult blood 
test (FOBT) in average-risk populations can detect asymptomatic colorectal cancers 
and precancerous lesions (high-risk adenomas). MethOds: We have reviewed the 
evidence about the quality, accessibility, and cost of screening using the FOBT to 
reduce colorectal cancer mortality. Such databases as Medline, PubMed, EMBASE 
were used. Results: Faecal occult blood test screening benefits include reduc-
tion in CRR mortality, possible reduction in cancer incidence through detection 
and removal of colorectal adenomas and potentially, treatment of early colorectal 
cancers may involve less invasive surgery. Thus, implementation of biennial faecal 
occult blood test screening is an efficient use of health resources. cOnclusiOns: 
The main objective for the improvement of cancer patients’ care is the introduction 
of national colorectal cancer screening programs based on evidence and available to 
people across the country. Introduction of clinical and cost-effectiveness screening 
methods in Ukraine and coordination of Ukrainian and world practices will provide 
timely and effective medical care for patients with CRR. In order to integrate these 
approaches into clinical practice based on evidence the clinical protocols are being 
developed.
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bAckgROund: There is ongoing debate over the extension of accelerated 
approval and conditional market authorisation initiatives, particularly for 
new cancer drugs in the US and Europe. This raises concerns for the benefit-
risk assessments of both regulators and payers when relying on early trial 
evidence. Methodological issues relating to immature clinical data and 
short-term follow-up, as well as the potential use of surrogate endpoints, 
may undermine these assessments and the resulting decisions made under 
conditions of uncertainty. In the context of health technology assessments 
(HTA) in the UK, we considered the impact on the probabilities of being the 
most effective and cost-effective treatment when reviewing available evi-
dence along the drug development and assessment processes. Objectives: 
To conduct a retrospective analysis of four NICE technology appraisals in pri-
mary breast cancer for HER-2 positive women alongside a simulation study to 
evaluate the relative effectiveness and cost-effectiveness of selected drugs over 
time. MethOds: We extracted data from TA107, TA108, TA109 and TA112 to ana-
lyse ‘snapshots’ of evidence at different time-points. Based on this example, we 
simulated individual patient characteristics and progression-free survival (PFS) 
times according to a predefined recruitment timeline. For both applied and simu-
lated datasets, we combined a network-meta-analysis and three-stage Markov 
economic model in WinBUGS to predict the joint impact of growing evidence net-
works on HTA results. The model allowed for different assumptions regarding the 
extrapolation of and the correlation between PFS and overall survival. Results: 
The magnitudes of credible intervals depended heavily upon the level of restriction 
used for follow-up. In addition, the performance of PFS as a surrogate endpoint 
strongly relied on the assumptions made on the correlation between the two 
endpoints. cOnclusiOns: Our analysis highlighted the inherent limitations and 
risks of early assessments with a substantial increase in the uncertainty of treat-
ment acceptability at thresholds of £20K and £30K.
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Objectives: Next Generation Sequencing (NGS) promises to find mutations 
(targets) in individual cancer patients, to subsequently assign targeted therapy. 
Currently, the technology itself is still in development and the effects on disease 
development, prognosis, or choice of therapy are still unclear. Besides informa-
tion for the current patient, additional (secondary) information for future patients 
can also become available. To accelerate the reimbursement process and have a 
NGS-panel available for patients in the earliest possible stage, early Technology 
Assessment (TA) is ongoing. In this project, we report on expert elicitation by 
means of scenario drafting, to provide qualitative and quantitative data to fill 
the evidence gaps in early cost-effectiveness modeling. MethOds: The follow-
ing steps in a multi-parameter framework can be distinguished: 1) Identifying 
(dynamic) aspects having impact on adoption; 2) Brainstorm on possible sce-
narios (informal interviews with NGS experts); 3) Scenario construction; 4) 
Validation of scenarios (semi-structured questionnaires to European NGS-experts); 
5) Quantification into parameters for cost-effectiveness modeling. Results: 
Based on the interviews and questionnaires (n= 29), the most likely scenarios as 
patients interest in NGS (likelihood 66,5% ±28,1); organizational readiness (84,4 
±18,5); advantage of including RNA, and the demand from the clinic (needs of 
medical staff) were identified as drivers for NGS development. Possible barrier 
scenarios were: number of actionable targets (55,2 ±23,7); demonstrating clinical 
utility (50,4 ±31,4); current evidence generation (65,5 ±27,9); consensus on panel 
for reimbursement (40,3% ±24,1); and competition within the field (64,2 ±21,9). 
Clustering into parameters for cost-effectiveness modeling resulted in: “failures”, 
“compliance”, “uptake”, and “future information”. cOnclusiOns: Although there 
are many issues to overcome to adopt NGS, the likelihood of NGS incorporation in 
clinical practice is very high. The “additional future information” is the most inter-
esting but complex variable to identify and to incorporate in cost-effectiveness 
modeling.
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Objectives: Most national standard therapeutic guidelines recommend a 52-week 
trastuzumab regimen for breast cancer treatment. In contrast, the Iranian national 
guideline (published by the Ministry of Health) recommends a nine-week regimen. We 
assessed the differences between current routine practice amongst Iranian specialists 
and the guidelines for trastuzumab treatment and HER2 receptor testing in breast 
cancer. MethOds: 128 Iranian hematology oncologists and radiotherapy oncologists 
were asked to complete an online anonymous questionnaire. Concurrently, a 3-year 
retrospective claims database analysis was conducted using data from the Social 
Security Organization, a health insurer which covers approximately 50% of the Iranian 
population, to enable comparisons with the questionnaire results. Results: With 
a 41% (52/128) response rate, doctors reported a relatively high absolute adherence 
(86%) to the guideline for HER2 receptor testing but a low rate of absolute adherence 
(6%) to the guideline for duration of trastuzumab treatment. Doctors indicated that 
the planned duration was 9 weeks in only 32% of patients; in most cases, the plan 
was 52-week treatment. Patients with a 9-week treatment plan received trastuzumab 
for 8.6 weeks on average while patients with 52-week plans received treatment for 
29.2 weeks. The general trends found in the survey were confirmed in the claims 
database analysis of 830 HER2 positive patients. cOnclusiOns: When it comes to 
trastuzumab use, Iranian doctors appear to rely more on the medical literature than 
on national guidelines developed by the Ministry of Health. Policymakers, doctors 
and the general public should try to reach some consensus about the optimal way to 
treat eligible patients. This is particularly necessary in low-middle income countries, 
whose limited budget cannot easily accommodate all of the innovative technologies 
to come. Inventive reimbursement policies may form part of the solution as long as 
the experiences from other countries are examined.
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Objectives: Trastuzumab (TRA) subcutaneous (SC) injection is an alternative to 
intravenous (IV) administration for the treatment of HER2+ early breast cancer (EBC). 
The objective was to quantify health care professional (HCP) time and patient chair 
time related to TRA treatment to estimate potential time and cost savings with a 
transition from IV to SC. MethOds: A multi-centre, prospective time-and-motion 
study was run in three Russian centres participating in the SafeHer clinical trial 
(MO28048). Case report forms listing pre-specified tasks for IV, SC, and pharmacy 
management in chronological order and tailored to site practices were used for data 
collection. Trained observers recorded patient chair time and durations that HCPs 
were actively completing the tasks. A random effects regression model was run for 
each task to generate mean and 95% confidence intervals. IV vs. SC process time was 
calculated as the sum of the mean task times. HCP and chair time were translated to 
cost using Russian salary data, and 354 roubles (p) per infusion chair hour. Results: 
Mean reduction in HCP time per patient session was 18.6min (-48%) (IV: 38.7min vs. 
SC: 20.1min; centre range: 8.6-31.1min), of which 61% of time reduced was achieved 
in the treatment room. Per treatment session (total 18 sessions), the estimated time 
saving was 5.6 hours (range across centres: 2.6-9.3hours). Reduction in mean chair 
time was 59.5min (-89%) (IV: 67.1min vs. SC: 7.6min; centre range: 29.8-97.3min). 
The monetary value of HCP and patient chair time saved was 1,175p and 6,314p, 
respectively, for 18 treatment sessions. cOnclusiOns: Transition from IV to SC TRA 
leads to substantial reductions in administration chair time, active HCP time and 
associated costs. This allows more time to be used for other patient care activities, 
increasing the number of patients who could be treated and thus increasing the 
overall efficiency of treatment centers.
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Objectives: The present study aimed to examine how breast cancer patients 
proceed through the public Greek health care system by using process mapping to 
identify constraints and bottlenecks and unnecessary process steps. MethOds: 
The sample of the study were 86 patients diagnosed with breast cancer at two 
large public oncological hospitals. A process mapping study, by applying PERT 
(Program Evaluation Review Technique) analysis, was conducted. Results: The 
total time spent for obtaining the treatment (per os or chemotherapy) is higher up 
to 7 times compared with the time spent in activities contributing directly towards 
the patient’s outcome. The average time needed to complete the procedure (e.g. 
physician consultation, waiting times, prescribing, obtaining pharmaceuticals) 
in Hospital A was 78.65 minutes (SD= 37.43) while waiting time was 51 minutes 
(64.9%). In Hospital B the respective time was 101 min (SD= 50.54) and 83.1% of that 
time was the waiting time. Similarly, the average time required for chemotherapy 
at Hospital A was 4 hours and 27 minutes (SD= 106.61) while the waiting time was 
2 hours and 15 minutes (50.8%). In Hospital B, the average time for chemotherapy 
was 3 hours 35 minutes (SD= 69.49) and 52.2% of that time was the waiting time. 
Among the main reasons for the delays were the lack of electronic records and 
poor function of the Central Information Prescribing System. cOnclusiOns: 
Waiting time represented the higher percentage of the total time needed to com-
plete the process for obtaining the treatment. As it represents one of the major 
causes for patient dissatisfaction, applying process mapping is a critical step for 
health care organizations to improve the beneficial time and the overall quality 
of the services offered.
0.2% (pancreas cancer) to 16.6% leukemia for females. Inconsistent changes were 
noticed for either incidence or mortality of different cancers. There were no sta-
tistically significant correlations between change in 5-year survival, and change 
in incidence and mortality for either male or female cancers during this period. 
When other time periods were considered for analysis, statistically significant 
correlations were noticed between change in 5-year survival and incidence of 
male cancers from 1981 to 1995 (Pearson r= 0.68; P= 0.03) and from 1986 to 1995 
(Pearson r= 0.78; P= 0.007). However, when the two mostly overdiagnosed cancers 
(prostate and breast) were excluded, there were no correlations between change 
in 5-year survival, and change in incidence and mortality for the three time peri-
ods. cOnclusiOns: Our study shows no reliable relationships between changes 
in 5-year survival and incidence or mortality. The increase in 5-year survival might 
not represent progress in cancer control, but instead indicate improved diagnosis 
and treatment in clinical practice.
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Objectives: Pilot study for evaluation of record linking and potential analysis of 
combination of epidemiologic cancer registry data and personalized pathway of 
care identified by billing data using lung cancer as test illness for Austrian data-
sets in the years 2006 till 2011. MethOds: Data sets are linked by anonymized 
distinct social insurance numbers of approximately 85 percent of all detected 
incident lung cancer patients in Austria in the years 2006 till 2011 with billing 
data on single person level. The calculated dataset deals as starting point for the 
analysis of the remaining lifetime distribution depending on age and TNM – state. 
Analysis of care classified by eight main categories given in hospitals coded by the 
MEL-system in combination with treatment using defined drugs is analysed and 
reported for further interpretation by the experts. An exploratory data analysis on 
the socio-economic standard and regional differences in Austrian federal states 
complete the pilot study. Results: Data for the whole Austrian health insured 
population, including incident cases for lung cancer over a time span of two years 
were analysed for the following chronic diseases detected by predefined rules 
on hospital diagnoses and drug prescription in the one year preceding patient 
history: COPD, diabetes and psychiatric illnesses. For the detected 6616 patients 
the probability of surviving is calculated and visualized by Kaplan-Meier-Curves. 
Exemplarily the one year survival is given: 75,44% and the 3-years life expectancy: 
~1% Further results combining different influence factors on survival including 
data from the cancer registry information table are performed. cOnclusiOns: 
Combining data collected by the national epidemiological cancer registry system 
and personalized pathways of patient treatment in intramural and extramural care 
provides a broad basis for analysis concerning real world pathway comparison 
of cancer patients. This work can unlock potential in respect of defining clinical 
national cancer registries.
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Objectives: Clinical oncology societies develop and regularly update evidence-
based guidelines in order to achieve more reliable and updated tools for patient 
management. In 2004 AIOM (Italian Association of Medical Oncology) created the 
RIGHT program: Research for the Identification of the most effective and hIGHly 
accepted clinical guidelines for cancer Treatment. It aims to evaluate the concord-
ance between AIOM breast (BC), colorectal (CRC) and lung (LC) cancer guidelines 
and clinical practice in Italian cancer centers. MethOds: the RIGHT program is 
composed by three retrospective observational studies, one for each guideline, 
conducted in a sample of 35 (BC) +37 (CRC) +53 (LC) Italian centers for cancer 
care representative of 230 AIOM centers. Site sampling from AIOM database was 
stratified by geographic distribution (North, Center, South). Indicators were iden-
tified to verify the concordance between AIOM guidelines and clinical practice 
about staging and treatment. Patients were included if they had their first visit 
at the site after guideline emission. Patients were then followed-up for at least 
6 months. Results: Patients enrolled for the breast, colorectal and lung cancer 
guideline evaluation were 324, 326, and 708, respectively. Adherence was on aver-
age 69% for BC, 76% for CRC and 69% for LC. For CRC adherence was 78% for colon, 
69% for rectal cancer and 83% for advanced disease. For BC, the lowest degree 
of compliance (0%) was observed for the follow-up indicator in asymptomatic 
patients. For LC, on average 67%, 46% and 81% of stage I-II-IIIA, IIIB and IV patients 
respectively received recommended care according to defined lung cancer indi-
cators cOnclusiOns: The RIGHT program showed that guidelines adherence 
is generally high, with very few cases of low adhererence. Guidelines adherence 
monitoring and update represent crucial activity to get more useful instrument 
to plan health care interventions.
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